About Us

At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity.

beigenemedical.info

Our platform provides state-of-the-art content for healthcare professionals in the field of cancer treatment. The future of cancer innovation is underway, and we are dedicated to sharing the knowledge.

“We think differently. We strive for innovation and excellence to make what seemed impossible into reality.”

John V. Oyler

Co-Founder, Chairman and CEO

“At BeiGene, we are dedicated to developing best-in-class anti-cancer therapies for China and the world. It’s an important mission and one we are intent on accomplishing.”

Xiaodong Wang

Chairman of Scientific Advisory Board & Co-Founder

Global Reach

From our start in Beijing with a handful of scientists and developers, we now have a global team, a rich pipeline, strong partnerships, and commercial products. We have no borders.

As part of our global clinical development program, we’re enrolling patients in 40+ countries and geographies to participate in our clinical trials.

Our Passion

At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity.

Science

The future of cancer innovation is underway, and we are dedicated to leading the charge.

BeiGene Cancer Biology Platform

Our focus is on molecularly targeted and immuno-oncology cancer therapeutics, both as monotherapies and for use in combination treatments, to have a meaningful and lasting impact on cancer patients.

Our development strategy facilitates R&D and commercialization around the world, with an emphasis on:

Independent R&D of Innovative oncology therapies

Molecularly Targeted Agents

Immuno-Oncology Therapies

Combination

Strategic collaboration with Global Partners

Established collaborations help leverage our capabilities in China and expand our portfolio

Evolution of BeiGene

An unprecedented journey to serve patients

†For a full listing of collaborative partners, please refer to slide: BeiGene – Striving to be the Partner of Choice CLL=chronic lymphocytic leukemia, FDA=Food and Drug Administration, IPO=initial public offering, MCL=mantle cell lymphoma, NDA=New Drug Application, R/R cHL=relapsed/refractory classical Hodgkin’s lymphoma, SLL=small lymphocytic lymphoma, WM=Waldenström macroglobulinemia 1. BeiGene. https://www.beigene.com/partnering/partnering-with-beigene. Accessed 30Oct20. 2. Dealogic data. 3. BeiGene Press Release. 17Jun21. Available at: https://ir.beigene.com/news-events/press-releases/. Accessed 13Aug21. 4. BeiGene Press Release. 08Apr21. Available at: https://ir.beigene.com/news-events/press-releases/. Accessed 13Aug21 5. BeiGene Press Release. 05Aug21. Available at: https://ir.beigene.com/news-events/press-releases/. Accessed 13Aug21

Lasting Impact

Recognized for our cancer research and drug development, the quality of our work, and our integrity.

BeiGene Key Principles

Patient-motivated

We are driven, by altruism and unrelenting curiosity, to develop innovative medicines intended to be accessible to large and broad populations.

Innovation-Driven

We have a novel and global business model intended to effectively and efficiently translate ground breaking science in to medical innovation.

Quality-Focused

To build a company that will have alasting impact, we are focused on doing everything to the highest standards of quality. There are noshortcuts to longevity.